NDATOPICALPATCH
Approved
Mar 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
LIDODERM (lidocaine) by Teikoku Seiyaku is clinical pharmacology pharmacodynamics lidocaine is an amide-type local anesthetic agent and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. First approved in 1999.
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIDODERM is a topical lidocaine 5% patch that delivers local anesthetic therapy through transdermal absorption to intact skin. It works by stabilizing neuronal membranes and inhibiting ionic fluxes required for pain impulse initiation and conduction. The patch is indicated for localized pain relief, with minimal systemic absorption (~3% of applied dose).
$0.003BPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Medicare spending ($3M in 2023), indicating consolidation of brand team and shift toward efficiency/generic preparation activities.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Lidocaine is an amide-type local anesthetic agent and is suggested to stabilize neuronal membranes by inhibiting the ionic fluxes required for the initiation and conduction of impulses. The penetration of lidocaine into intact skin after application of…
Worked on LIDODERM at Teikoku Seiyaku? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.